U.S. markets closed

Gritstone Oncology, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.08+0.51 (+3.76%)
At close: 4:00PM EST

13.91 -0.17 (-1.21%)
After hours: 5:21PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close13.57
Bid14.05 x 900
Ask14.08 x 800
Day's Range13.51 - 14.40
52 Week Range2.54 - 35.20
Avg. Volume3,254,696
Market Cap687.001M
Beta (5Y Monthly)0.38
PE Ratio (TTM)N/A
EPS (TTM)-2.87
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 4 Top COVID Stocks to Buy in February
    Motley Fool

    4 Top COVID Stocks to Buy in February

    Are you a high-risk stock picker or cautious investor? No matter your answer, there's a stock for you on this list.

  • Biotech Stock Gritstone Stumbles On Gilead Tie-Up, While Arcus Pops
    Investor's Business Daily

    Biotech Stock Gritstone Stumbles On Gilead Tie-Up, While Arcus Pops

    Gilead Sciences announced a partnership in HIV with Gritstone Oncology, and upped its stake in Arcus Biosciences. Biotech stock Arcus jumped, but Gritstone fell at the stock market's close.

  • MarketWatch

    Gritstone Oncology shares soar 44% premarket on news of collaboration with Gilead to develop HIV therapy

    Shares of Gritstone Oncology Inc. soared 44% in premarket trade Monday, after the company unveiled an agreement with Gilead Sciences Inc. to use Gritstone's vaccine platform technology to develop a treatment for HIV. "Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone's proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead," the companies said in a statement. Under the terms of the deal, Gritstone will receive an upfront payment of $60 million, comprising a $30 million cash payment and a $30 million equity investment at a premium. Gilead will conduct a Phase I study for the therapeutic vaccine and hold an exclusive option to obtain an exclusive license to develop and commercialize the vaccine beyond Phase 1. Gritstone will be entitled to up to an additional $725 million if the option is exercised and certain clinical, regulatory and commercial milestones are met, as be entitled to mid single-digit to low double-digit tiered royalties on net sales. "While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy," said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. "Curing HIV remains the ultimate aspiration for Gilead's HIV research and development efforts." Gilead shares rose 0.5% premarket. Gritstone shares have gained 104% in the last 12 months, while the S&P 500 has gained 15%.